An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

NCT02253992 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

232

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Advanced B-cell NHL

Interventions

BIOLOGICAL: Urelumab
BIOLOGICAL: Nivolumab

Sponsor

Bristol-Myers Squibb